Validation of Korean Version of the COmprehensive Score for Financial Toxicity (COST) among Breast Cancer Survivors

被引：16

作者：

Shim, Sungkeun ^{[1
,2
]}

Kang, Danbee ^{[2
,3
]}

Kim, Nayeon ^{[3
,4
]}

Han, Gayeon ^{[2
]}

Lim, Jihyun ^{[2
]}

Kim, Hyunsoo ^{[1
,2
]}

Park, Jeonghyun ^{[3
]}

Lee, Mankyung ^{[1
,2
]}

Lee, Jeong Eon ^{[5
]}

Kim, Seok Won ^{[5
]}

Yu, Jonghan ^{[5
]}

Chae, Byung Joo ^{[5
]}

Ryu, Jai Min ^{[5
]}

Nam, Seok Jin ^{[5
]}

Lee, Se Kyung ^{[5
]}

Cho, Juhee ^{[2
,3
,4
,6
,7
,8
]}

机构：

[1] Sungkyunkwan Univ, SAIHST, Dept Digital Hlth, Seoul, South Korea

[2] Samsung Med Ctr, Ctr Clin Epidemiol, Seoul, South Korea

[3] Sungkyunkwan Univ, SAIHST, Dept Clin Res Design & Evaluat, 115 Irwon Ro, Seoul 06355, South Korea

[4] Samsung Med Ctr, Canc Educ Ctr, Seoul, South Korea

[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Breast Surg,Dept Surg, 81 Irwon Ro, Seoul 06351, South Korea

[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[7] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Med, Baltimore, MD USA

[8] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA

来源：

CANCER RESEARCH AND TREATMENT | 2022年 / 54卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

Financial stress; Quality of life; Breast neoplasms; Cancer survivors; Validation study; QUALITY-OF-LIFE; BURDEN; DISTRESS; ADULTS; HEAD;

D O I：

10.4143/crt.2021.784

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors. Materials and Methods We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques. Results The COST-K demonstrated good internal consistency, with a Cronbach's a of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=-0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, -0.18; constipation, -0.14; diarrhea, -0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean +/- standard deivation [SD], 27.1 +/- 7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity. Conclusion The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.

引用

页码：834 / 841

页数：8

共 29 条

[1] Financial burden amongst cancer patients treated with curative intent surgery alone [J].